The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Therapeutic Advances in Urology

• Publication date

  2015-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1756287215589250PMID 26445596PMCID PMC4580095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

  2014cited by this paper
• Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

  2014cited by this paper
• Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

  2013cited by this paper
• Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

  2013cited by this paper
• Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

  2013cited by this paper
• Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial

  2013cited by this paper
• Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

  2013cited by this paper
• A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

  2013cited by this paper
• Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

  2012cited by this paper
• Patient‐reported reasons for discontinuing overactive bladder medication

  2010cited by this paper
• Reviewing the ICS 2002 terminology report: The ongoing debate

  2009cited by this paper
• Persistence of antimuscarinic drug use

  2009cited by this paper
• Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

  2008cited by this paper
• Persistence, Adherence, and Switch Rates Among Extended-Release and Immediate-Release Overactive Bladder Medications in a Regional Managed Care Plan

  2008cited by this paper
• Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

  2008cited by this paper
• Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.

  2006cited by this paper
• Reviewing the ICS 2002 terminology report: The ongoing debate

  2006cited by this paper
• Solifenacin significantly improves all symptoms of overactive bladder syndrome

  2006cited by this paper
• Current and future challenges facing academic medicine

  2006cited by this paper
• Persistence with overactive bladder pharmacotherapy in a Medicaid population.

  2005cited by this paper
• Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

  2004cited by this paper
• Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

  2004cited by this paper
• TRIALS REVIEW Open Access

  year unknowncited by this paper

• Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials.

  2026cites this paper
• Interventions for treating urinary incontinence in older women: a network meta-analysis.

  2025cites this paper
• Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder – A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence

  2025cites this paper
• Uso de recursos y carga socioeconómica asociada a adultos con vejiga hiperactiva en tratamiento farmacológico en España

  2024cites this paper
• Adrenergic relaxations in an in situ urinary bladder model evoked by stimulation of sensory pelvic and pudendal nerves in the rat.

  2024cites this paper
• Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database

  2024cites this paper
• Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome

  2024cites this paper
• Comparison of Mirabegron and Solifenacin for the Management of Urge Incontinence in Menopausal Age Group

  2024cites this paper
• Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.

  2024cites this paper
• Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials.

  2023cites this paper
• Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders

  2023cites this paper
• A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder

  2023cites this paper
• Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis

  2023cites this paper
• Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.

  2023cites this paper
• Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.

  2023cites this paper
• Re: Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.

  2023cites this paper
• THE SAFETY AND EFFICACY OF SOLIFENACIN AS COMPARED TO MIRABEGRON IN OVERACTIVE BLADDER SYNDROME PATIENTS IN THE ADULT POPULATION OF DERA ISMAIL KHAN

  2023cites this paper
• Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice

  2022cites this paper
• Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis

  2022cites this paper
• Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently

  2022cites this paper
• Mirabegron in the Management of Overactive Bladder Syndrome

  2022cites this paper
• Solifenacin and Mirabegron Monotherapies Versus Combination Therapy in Overactive Bladder: A Prospective Observational Study

  2022cites this paper
• Solifenacin-induced acute urticaria and angioedema: a rare adverse effect

  2021cites this paper
• A systematic review and meta-analysis

  2021cites this paper
• Treatment Options in Patients with Overactive Bladder: Initial and Pharmacological Management

  2021cites this paper
• Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.

  2021cites this paper
• Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care

  2021cites this paper
• Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia

  2021cites this paper
• Potential of mirabegron and its extended-release formulations for the treatment of overactive bladder syndrome.

  2020cites this paper
• Pharmacology of the lower urinary tract: update on LUTS treatment

  2020cites this paper
• Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”

  2020cites this paper
• A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)

  2020influential citation
• Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis

  2020cites this paper
• Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study

  2020cites this paper
• Mirabegrone versus Solifenacine in Treatment of Overactive Bladder in Female Patients in Zagazig University Hospitals

  2020cites this paper
• Ethological and physiological side effects of oxybutynin studied on ants as models

  2020cites this paper
• Side effects of mirabegron studied on ants as models

  2020cites this paper
• The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.

  2019cites this paper
• Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.

  2019cites this paper
• Effectiveness and persistence of mirabegron as a first‐line treatment in patients with overactive bladder in real‐life practice

  2019cites this paper
• Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder

  2019cites this paper
• Updating the evidence on drugs to treat overactive bladder: a systematic review

  2019cites this paper
• Diagnosis and Management of Bladder Dysfunction in Neurologically Normal Children

  2019cites this paper
• Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

  2019cites this paper
• Treatment of Storage LUTS

  2019cites this paper
• Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study

  2019cites this paper
• Recent Non-neurogenic Overactive Bladder Trials

  2019cites this paper
• Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.

  2019cites this paper
• Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB)

  2019cites this paper
• Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?

  2019cites this paper
• Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis

  2018influential citation
• Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3‐Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?

  2018cites this paper
• Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder

  2018cites this paper
• Management der überaktiven Blase unter Berücksichtigung der posterioren tibialen Nervenstimulation

  2018cites this paper
• EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence.

  2018cites this paper
• Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

  2018cites this paper
• Nocturia and associated mortality: observational data from the REDUCE trial

  2018cites this paper
• Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms

  2018cites this paper
• Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.

  2018cites this paper
• Urinary Urgency in the Elderly

  2018cites this paper
• The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy

  2018cites this paper
• Mirabegron: A Review in Overactive Bladder Syndrome

  2018influential citation
• Medical treatment of female overactive bladder syndrome and treatment-related effects.

  2018cites this paper
• Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

  2017cites this paper
• Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia

  2017cites this paper
• No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.

  2017cites this paper
• Does zinc with and without iron co-supplementation have effect on motor and mental development of children? A systematic review and meta-analysis

  2017cites this paper
• [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].

  2017cites this paper
• Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

  2017cites this paper
• No 353 - Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie - Addenda.

  2017cites this paper
• A novel standard to evaluate the impact of therapeutic agents on patient safety – The BURDEN OF THERAPY™©∗

  2016cites this paper
• High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment

  2016cites this paper
• A drug safety evaluation of mirabegron in the management of overactive bladder

  2016influential citation
• Urinary incontinence in men: current and developing therapy options

  2016cites this paper
• Platinum Priority – Voiding Dysfunction

  2016cites this paper
• Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

  2016cites this paper
• Mirabegron in overactive bladder patients: efficacy review and update on drug safety

  2016cites this paper
• . Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised, Double-blind, Multicentre, Phase 3b Study (BESIDE). European Urology

  2016cites this paper
• SYSTEMATIC REVIEW OF THE EFFICARY, SAFETY AND COST-EFFECTIVENESS OF MIRABEGRON IN COMPARISON WITH SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER

  year unknowncites this paper